MASSDEVICE ON CALL — Shareholders at Johnson & Johnson‘s (NYSE:JNJ) annual meeting had much to say about the company’s recent slew of high-profile product quality issues.
Outgoing CEO William Weldon and successor Alex Gorsky assured J&J stakeholders that the company had a plan to recover its tarnished image, the Associated Press reported.
"Are you going to be implementing more careful procedures to ensure that Johnson & Johnson continues to be the honorable company that it’s always been?" asked one attendee.
Health care experts look to the skies for clues on how to best manage patient safety, modeling some formulas from best practices learned in aviation. Read more
Madison, Wisc.-based regenerative medicine company Stratatech Corp. announced positive results from ongoing clinical trials of its StrataGraft universal human skin substitute. Read more
Med-tech titan Medtronic (NYSE:MDT) touted positive 6-month outcomes of its Symplicity renal denervation system as treatment for hypertension. Read more
A new study finds that mortality rates among elderly patients with multiple health issues were 3 higher for those cared for through home health technologies as opposed to standard care. Read more
A new breakthrough in 3D X-ray technology reveals the tissue fibers in the heart that may be disturbed in patients with abnormal heart rhythms. Read more
